Edition:
United States

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.55USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,426
52-wk High
$2.95
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial
Monday, 14 May 2018 04:05pm EDT 

May 14 (Reuters) - Chiasma Inc ::CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL.CHIASMA - FOURTH, FIFTH SECONDARY ENDPOINTS IN PHASE 3 TRIAL NOW BEEN REDEFINED TO DESCRIPTIVE STATISTICS MEASURED WITHIN EACH TREATMENT GROUP.CHIASMA INC - UNDER SPA AGREEMENT MODIFICATION FOR CHIASMA OPTIMAL PHASE 3 TRIAL, BETWEEN-ARM COMPARISONS OF 2 DESCRIPTIVE MEASURES WILL NOT BE MADE.CHIASMA INC - FDA INDICATED IT PLANS TO CONSIDER SECONDARY ENDPOINTS IN ITS EVALUATION OF TOTALITY OF EVIDENCE OF ORAL OCTREOTIDE'S TREATMENT EFFECT.  Full Article

Chiasma Reports Q1 Loss Per Share $0.29
Thursday, 10 May 2018 04:05pm EDT 

May 10 (Reuters) - Chiasma Inc ::CHIASMA REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.29.CHIASMA - EXPECTS EXISTING CASH, INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF DATA FROM CHIASMA OPTIMAL TRIAL BY 2019 END.  Full Article

Chiasma Inc Files For Mixed Shelf Of Up To $100 Million ‍​
Thursday, 22 Mar 2018 04:45pm EDT 

March 22 (Reuters) - Chiasma Inc ::CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​.  Full Article

Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln
Monday, 8 Jan 2018 09:00am EST 

Jan 8 (Reuters) - Chiasma Inc ::CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION.CHIASMA-EXISTING CASH TO BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF TOP-LINE DATA FROM CHIASMA OPTIMAL PHASE 3 TRIAL BY 2019 END.  Full Article

Chiasma Q3 loss per share $0.28
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Chiasma Inc ::Chiasma reports third quarter 2017 results.Q3 loss per share $0.28.Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​.  Full Article

Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly
Wednesday, 27 Sep 2017 04:05pm EDT 

Sept 27 (Reuters) - Chiasma Inc :Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly.Chiasma Inc - Meeting its previous guidance that enrollment in study would begin during second half of 2017​.Chiasma Inc - ‍Announced it has recently surpassed 50% patients randomized in its international phase 3 clinical trial​.  Full Article

Chiasma Q2 loss per share $0.28
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reports second quarter 2017 results.Q2 loss per share $0.28.Chiasma Inc - expect to have a cash and investment balance of at least $60 million at end of 2017.  Full Article

Chiasma reached deal with FDA on late-stage trial of its acromegaly drug
Thursday, 10 Aug 2017 04:00pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma reaches agreement with fda under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma Inc - ‍plans to initiate enrollment in new phase 3 clinical trial - optimal - during second half of 2017​.Chiasma Inc - ‍anticipates release of top-line data from new optimal trial by end of 2019​.Says "‍based on our current plans, we expect to have a cash and investment balance of at least $60 million at end of 2017"​.  Full Article

Chiasma reports Q1 loss per share $0.29
Friday, 5 May 2017 08:01am EDT 

May 5 (Reuters) - Chiasma Inc : :Chiasma reports first quarter 2017 results.Q1 loss per share $0.29.Chiasma Inc - following receipt of crl for octreotide capsules NDA, company participated in an end of review meeting with FDA.Chiasma Inc - FDA "reiterated its strong preference" for a randomized, double-blind and controlled trial for octreotide capsules.Chiasma Inc - for octreotide capsules, FDA suggested that some of its concerns could potentially be addressed through placebo-controlled study design.Chiasma Inc - FDA advised in CRL that, during a site inspection, certain deficiencies were conveyed to representative of one of Chiasma's suppliers.Chiasma Inc - in December 2016, supplier informed chiasma that it had received its establishment inspection report from FDA.Chiasma Inc - expects its existing cash, cash equivalents and marketable securities to fund operations beyond 2018.  Full Article

Chiasma Q4 loss per share $0.32
Thursday, 16 Mar 2017 04:05pm EDT 

Chiasma Inc : Chiasma reports fourth quarter and year end 2016 results . Q4 loss per share $0.32 .Chiasma Inc - for quarter ended december 31, 2016, net loss attributable to common stockholders was $7.9 million, or $0.32 per basic share..  Full Article

BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial

* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL